Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

Supplements and Featured Publications, Mapping Clinical Updates in Myelodysplastic Syndromes, Volume 1, Issue 1

In Partnership With:

Partner | Cancer Centers | <b>The University of Texas MD Anderson Cancer Center</b>

Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by Bristol Myers Squibb, we had the pleasure of speaking with Guillermo Garcia-Manero, MD, about research in myelodysplastic syndromes (MDS) that was presented at the 2024 EHA Congress. Dr Garcia-Manero is a professor, chief of the section of Myelodysplastic Syndromes, and deputy chair of Translational Research in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.

In our exclusive interview, Dr Garcia-Manero discussed findings from a post hoc analysis of the phase 3 COMMANDS trial (NCT03682536) evaluating the relationship between hemoglobin levels and quality of life in transfusion-dependent patients with lower-risk MDS receiving luspatercept-aamt (Reblozyl) or epoetin alfa; real-world dose-escalation outcomes among patients with lower-risk MDS receiving luspatercept; and multilineage and safety findings from the COMMANDS trial.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by Bristol Myers Squibb. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.